
PD173074
CAS No. 219580-11-7
PD173074( PD173074 | PD 173074 | PD-173074 )
Catalog No. M13497 CAS No. 219580-11-7
PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 32 | In Stock |
![]() ![]() |
10MG | 47 | In Stock |
![]() ![]() |
25MG | 82 | In Stock |
![]() ![]() |
50MG | 129 | In Stock |
![]() ![]() |
100MG | 210 | In Stock |
![]() ![]() |
200MG | 372 | In Stock |
![]() ![]() |
500MG | 620 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NamePD173074
-
NoteResearch use only, not for human use.
-
Brief DescriptionPD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
-
DescriptionPD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
-
In Vitro——
-
In Vivo——
-
SynonymsPD173074 | PD 173074 | PD-173074
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR| FGFR1| Insulin Receptor| c-Src| VEGFR2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number219580-11-7
-
Formula Weight523.67
-
Molecular FormulaC28H41N7O3
-
Purity>98% (HPLC)
-
SolubilityEthanol: 100 mg/mL (190.95 mM); DMSO: 100 mg/mL (190.95 mM)
-
SMILESO=C(NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C3=CC(OC)=CC(OC)=C3)NC(C)(C)C
-
Chemical Name1-(tert-butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904.
molnova catalog



related products
-
PD173074
PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
-
Barecetamab
Barecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity for use in investigational stage malignant solid tumors.
-
AZD-9291
A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.